Thermo Fisher Scientific Inc. $TMO Stock Holdings Lifted by BankPlus Trust Department

BankPlus Trust Department lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 2,752 shares of the medical research company’s stock after buying an additional 121 shares during the quarter. BankPlus Trust Department’s holdings in Thermo Fisher Scientific were worth $1,116,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Shell Asset Management Co. lifted its position in shares of Thermo Fisher Scientific by 6.6% in the 2nd quarter. Shell Asset Management Co. now owns 22,472 shares of the medical research company’s stock worth $9,111,000 after buying an additional 1,390 shares during the last quarter. Slow Capital Inc. raised its position in shares of Thermo Fisher Scientific by 1.5% during the 2nd quarter. Slow Capital Inc. now owns 7,442 shares of the medical research company’s stock worth $3,019,000 after buying an additional 112 shares in the last quarter. KLP Kapitalforvaltning AS grew its stake in shares of Thermo Fisher Scientific by 4.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 142,683 shares of the medical research company’s stock worth $57,904,000 after purchasing an additional 5,600 shares during the last quarter. RMG Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $131,000. Finally, Hardy Reed LLC grew its stake in shares of Thermo Fisher Scientific by 96.9% in the 2nd quarter. Hardy Reed LLC now owns 5,060 shares of the medical research company’s stock worth $2,052,000 after purchasing an additional 2,490 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company’s stock, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last ninety days. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on TMO shares. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Evercore ISI lifted their target price on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research report on Tuesday. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Raymond James Financial reissued an “outperform” rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $591.16.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $539.54 on Wednesday. The firm has a fifty day simple moving average of $484.90 and a 200-day simple moving average of $447.60. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The stock has a market capitalization of $203.73 billion, a price-to-earnings ratio of 31.21, a PEG ratio of 2.95 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. During the same period in the previous year, the company earned $5.37 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.